-
Parkinson's Disease, Ashkenazi Jews and LRRK2: a consortium proposal
… or expression of this mutation is broad; PD can begin early or late in life and its course is variable. The … treatments. Project Description: In order to gain insight into how LRRK2 causes PD, including possible gene modifiers, … and their families towards genetic testing. Relevance to Diagnosis/Treatment of Parkinson’s Disease: This study is …
-
In-vivo SPECT Imaging of Synuclein Aggregation with Morphology Specific Antibody Based Ligands
… This grant builds upon the research from a prior grant: In Vivo SPECT Imaging of … PD, and small a-syn aggregates are very toxic and may be an early indicator of the disease. We have developed ligands … sequences that have been shown to facilitate transfer into the brain to the a-syn ligand, and determine which …
-
Exosome/Microvesicle Release from LRRK2 Mutant iPSC-derived Neural Cells
… identification of Parkinson's disease. Project Description: Researchers will utilize induced pluripotent stem cell lines … gene. Cells will be grown in culture and differentiated into neural cells. The conditioned medium from the cells … to identify neural-specific microvesicles. Relevance to Diagnosis/Treatment of Parkinson’s Disease: …
-
Saliva Alpha-synuclein Levels in LRRK2 Mutation Carriers
… Rationale: Biomarkers are needed to assist with the diagnosis of Parkinson’s disease (PD) and with monitoring … LRRK2 mutations utilizing one or more assays. Impact on Diagnosis/Treatment of Parkinson’s Disease: Human salivary … inexpensive, easily accessible biomarker to 1) assist with early PD diagnosis when treatment could be most effective, …
-
New Imaging Agents for Parkinson's Disease and Related Disorders
… This grant builds upon the research from a prior grant: Development of PET Tracers for … emission tomography (PET) imaging to diagnose Parkinson's early and track disease progression, as well as monitor the … experimental setups to accomplish these goals. Impact on Diagnosis/Treatment of Parkinson's Disease: An imaging agent …
-
Assessment of the Novel Neuronal Synuclein Disease Staging System in Stratifying Dementia with Lewy Bodies Patients
… (AD). Similar to Parkinson's disease (PD), DLB falls into the category of synucleinopathies, disorders that … centers across Europe focused on clinical translational research on DLB. We will use the NSD staging system to … categorize patients within the E-DLB that have received a diagnosis and have contributed both cerebrospinal fluid …